Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ocumension TherapeuticsOCUTF 53 Days Sales Outstanding is 91.07 as of Dec. 2025, which is 49% below its 10-year median of 177.81. GuruFocus rates OCUTF with a GF Score™ of 53/100 and a GF Value™ of $2.61 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 836 Biotechnology companies, Ocumension Therapeutics ranks worse than 69.62% on this metric.
Ocumension Therapeutics (OTCPK:OCUTF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Ocumension Therapeutics Days Sales Outstanding Related Terms
Ocumension Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Ocumension Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocumension Therapeutics Days Sales Outstanding Chart
OCUTF vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Ocumension Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumension Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Ocumension Therapeutics's Days Sales Outstanding falls into.
Ocumension Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocumension Therapeutics (OCUTF) has a Days Sales Outstanding of 91.07 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ocumension Therapeutics and its competitors. This is 49% below median its historical median of 177.81. Over the past decade, Ocumension Therapeutics' Days Sales Outstanding has ranged from 101.64 to 26,141.61. According to the industry distribution chart, Ocumension Therapeutics ranks #582 out of 836 companies in the Biotechnology industry, placing it in the top 69.6%.
Is Ocumension Therapeutics' Days Sales Outstanding too high?
Ocumension Therapeutics' current Days Sales Outstanding of 91.07 is 49% below median its 10-year median of 177.81. Over the past 10 years, this metric has ranged from a low of 101.64 to a high of 26,141.61. The Biotechnology industry median Days Sales Outstanding is 69.09. Ocumension Therapeutics' value of 91.07 is 31.8% above this industry median. Based on the distribution chart, Ocumension Therapeutics ranks #582 out of 836 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ocumension Therapeutics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ocumension Therapeutics ranks #582 out of 836 companies for Days Sales Outstanding. This places Ocumension Therapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 69.09. Ocumension Therapeutics' value of 91.07 is 31.8% above this benchmark. Historically, Ocumension Therapeutics' own Days Sales Outstanding has ranged from 101.64 to 26,141.61 over the past decade. While the company's 10-year median is 177.81 vs. the industry median of 69.09, Ocumension Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.09, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocumension Therapeutics's current Days Sales Outstanding of 91.07 is 31.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ocumension Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocumension Therapeutics's current Days Sales Outstanding is 91.07, which is 49% below median its own 10-year median of 177.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.61, compared to a current price of $0.70 — trading 73.2% below its estimated fair value. The current Days Sales Outstanding is 91.07, which is 49% below median its 10-year median of 177.81 and 31.8% above the Biotechnology industry median of 69.09. Ocumension Therapeutics' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current Days Sales Outstanding is 91.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?
Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued.
The current stock price of $0.70 is trading 73.2% below its estimated GF Value™ of $2.61.
GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.
Key valuation signals for OCUTF:
Days Sales Outstanding: 91.07 (49% below median its 10-year median of 177.81)
GF Value™: $2.61 vs. price of $0.70 (73.2% below fair value)
Industry Position: 31.8% above the Biotechnology median (#582 of 836)
No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
53GF Score
Get the complete analysis for OCUTF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCUTF has been successfully added to your 
